Blank Cover Image

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.

フォーマット:
論文
責任表示:
Xu, Liang ; Nagata, Naoto ; Nagashimada, Mayumi ; Zhuge, Fen ; Ni, Yinhua ; Chen, Guanliang ; Mayoux, Eric ; Kaneko, Shuichi ; Ota, Tsuguhito ; 長田, 直人 ; 金子, 周一 ; 太田, 嗣人
言語:
英語
出版情報:
Elsevier, 2017-07
著者名:
Xu, Liang
Nagata, Naoto
Nagashimada, Mayumi
Zhuge, Fen
Ni, Yinhua
Chen, Guanliang
Mayoux, Eric
Kaneko, Shuichi
Ota, Tsuguhito
長田, 直人
金子, 周一
太田, 嗣人
続きを見る
掲載情報:
EBioMedicine
ISSN:
2352-3964  CiNii Research  Webcat Plus  JAIRO
巻:
20
開始ページ:
137
終了ページ:
149
バージョン:
publisher
概要:
金沢大学医薬保健研究域医学系<br />Sodium-glucose cotransporter (SGLT) 2 inhibitors increase urinary glucose excretion (UGE), leading to blood glucose reductions and weight loss. However, the impacts of SGLT2 inhibition on energy homeostasis and obe sity-induced insulin resistance are less well known. Here, we show that empagliflozin, a SGLT2 inhibitor, enhanced energy expenditure and attenuated inflammation and insulin resistance in high-fat-diet-induced obese (DIO) mice. C57BL/6J mice were pair-fed a high-fat diet (HFD) or a HFD with empagliflozin for 16 weeks. Empagliflozin administration increased UGE in the DIO mice, whereas it suppressed HFD-induced weight gain, insulin resistance, and hepatic steatosis. Moreover, empagliflozin shifted energy metabolism towards fat utilization, elevated AMP-activated protein kinase and acetyl-CoA carbolxylase phosphorylation in skeletal muscle, and increased hepatic and plasma fibroblast growth factor 21 levels. Importantly, empagliflozin increased energy expenditure, heat production, and the expression of uncoupling protein 1 in brown fat and in inguinal and epididymal white adipose tissue (WAT). Furthermore, empagliflozin reduced M1-polarized macrophage accumulation while inducing the anti-inflammatory M2 phenotype of macrophages within WAT and liver, lowering plasma TNFα levels and attenuating obesity-related chronic inflammation. Thus, empagliflozin suppressed weight gain by enhancing fat utilization and browning and attenuated obesity-induced inflammation and insulin resistance by polarizing M2 macrophages in WAT and liver. 続きを見る
URL:
http://hdl.handle.net/2297/00050482
タイトル・著者・出版者が同じ資料

類似資料:

1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 

Xu, Liang, Nagata, Naoto, Nagashimada, Mayumi, Zhuge, Fen, Ni, Yinhua, Chen, Guanliang, Kamei, Junzo, Ishikawa, Hiroki, &hellip;

Impact Journals LLC

Oguma, Keisuke, Oshima, Hiroko, Aoki, Masahiro, Uchio, Ryusei, Naka, Kazuhito, Nakamura, Satoshi, Hirao, Atsushi, Saya, &hellip;

Nature Publishing Group

Ni, Yinhua, Nagashimada, Mayumi, Zhuge, Fen, Zhan, Lili, Nagata, Naoto, Tsutsui, Akemi, Nakanuma, Yasuni, Kaneko, &hellip;

Nature Publishing Group

Nagata, Naoto, Xu, Liang, Kohno, Susumu, Ushida, Yusuke, Aoki, Yudai, Umeda, Ryohei, Fuke, Nobuo, Zhuge, Fen, Ni, &hellip;

American Diabetes Association = American Diabetes Association

諸葛, 芬, Zhuge, Fen

金沢大学十全医学会, The Juzen Medical Society Kanazawa University

Urai, Tamae, Nakajima, Yukari, Mukai, Kanae, Asano, Kimi, Okuwa, Mayumi, Sugama, Junko, Nakatani, Toshio, 中島, &hellip;

Scientific Research Publishing

Xu, Liang, Nagata, Naoto, Ota, Tsuguhito, 長田, 直人, 太田, 嗣人

Taylor & Francis